MX2020009579A - Vectores de adn sintetico y metodos de uso. - Google Patents

Vectores de adn sintetico y metodos de uso.

Info

Publication number
MX2020009579A
MX2020009579A MX2020009579A MX2020009579A MX2020009579A MX 2020009579 A MX2020009579 A MX 2020009579A MX 2020009579 A MX2020009579 A MX 2020009579A MX 2020009579 A MX2020009579 A MX 2020009579A MX 2020009579 A MX2020009579 A MX 2020009579A
Authority
MX
Mexico
Prior art keywords
dna vectors
methods
dna
synthetic dna
subject
Prior art date
Application number
MX2020009579A
Other languages
English (en)
Inventor
Bruce C Schnepp
Philip R Johnson
Original Assignee
Intergalactic Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Intergalactic Therapeutics Inc filed Critical Intergalactic Therapeutics Inc
Publication of MX2020009579A publication Critical patent/MX2020009579A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/711—Natural deoxyribonucleic acids, i.e. containing only 2'-deoxyriboses attached to adenine, guanine, cytosine or thymine and having 3'-5' phosphodiester links
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/713—Double-stranded nucleic acids or oligonucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/0008—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/0075—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the delivery route, e.g. oral, subcutaneous
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14141—Use of virus, viral particle or viral elements as a vector
    • C12N2750/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Zoology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Wood Science & Technology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Epidemiology (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Virology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

Se proporcionan en la presente vectores de ADN aislados que comprenden un gen heterólogo, donde el vector de ADN está desprovisto de ADN de plásmido bacteriano y/o firmas bacterianas, lo cual puede abrogar la persistencia in vivo. La invención también presenta composiciones farmacéuticas (composiciones farmacéuticas no inmunogénicas) que incluyen los vectores de ADN de la invención, las cuales pueden usarse para la inducción de expresión episomal a largo plazo, de un gen heterólogo en un sujeto. La invención involucra métodos de tratamiento de un sujeto administrando los vectores de ADN de la invención, incluyendo métodos de tratamiento de trastornos asociados con un defecto en un gen objetivo.
MX2020009579A 2018-03-15 2019-03-15 Vectores de adn sintetico y metodos de uso. MX2020009579A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862643336P 2018-03-15 2018-03-15
US201862749369P 2018-10-23 2018-10-23
PCT/US2019/022511 WO2019178500A1 (en) 2018-03-15 2019-03-15 Synthetic dna vectors and methods of use

Publications (1)

Publication Number Publication Date
MX2020009579A true MX2020009579A (es) 2020-11-09

Family

ID=67908049

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2020009579A MX2020009579A (es) 2018-03-15 2019-03-15 Vectores de adn sintetico y metodos de uso.

Country Status (10)

Country Link
US (2) US20210002667A1 (es)
EP (1) EP3765023A4 (es)
JP (2) JP2021516953A (es)
KR (1) KR20200132893A (es)
CN (2) CN117757842A (es)
AU (1) AU2019233901A1 (es)
CA (1) CA3092088A1 (es)
IL (1) IL276923A (es)
MX (1) MX2020009579A (es)
WO (1) WO2019178500A1 (es)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12403305B2 (en) 2016-06-27 2025-09-02 Galvanize Therapeutics, Inc. Immunostimulation in the treatment of viral infection
EP3474760B1 (en) 2016-06-27 2023-01-11 Galvanize Therapeutics, Inc. Generator and a catheter with an electrode for treating a lung passageway
US20200048716A1 (en) * 2017-11-03 2020-02-13 Twister Biotech, Inc Using minivectors to treat ovarian cancer
DK3731771T3 (da) 2017-12-26 2023-08-28 Galvanize Therapeutics Inc V462033dk00
SG11202103917VA (en) 2018-10-16 2021-05-28 Blueallele Llc Methods for targeted insertion of dna in genes
CN118203401A (zh) 2019-04-18 2024-06-18 盖能适治疗股份有限公司 用于治疗异常组织的装置、系统和方法
KR20220128607A (ko) 2019-09-18 2022-09-21 인터갈락틱 테라퓨틱스, 인크. 합성 dna 벡터 및 사용 방법
EP4192572A4 (en) 2020-08-04 2024-08-21 Galvanize Therapeutics, Inc. TRANSFER OF MOLECULES BY PULSED ELECTRIC FIELD TO CELLS IN THE ORGANISM
CN116829691A (zh) 2020-08-04 2023-09-29 盖能适治疗股份有限公司 分子到体内细胞的脉冲电场转移
EP4298214A4 (en) * 2021-02-23 2025-03-19 Aldevron, LLC NUCLEIC ACID VECTORS AND METHODS OF USE
CN118056012B (zh) * 2021-08-24 2025-05-30 赛斯尔擎生物技术（上海）有限公司 一种修饰细胞的方法
WO2023064934A1 (en) * 2021-10-15 2023-04-20 Intergalactic Therapeutics, Inc. Respiratory delivery of therapeutic agents
EP4522758A4 (en) * 2022-05-13 2026-05-06 Ascidian Therapeutics Inc Abca4 trans-splicing molecules
CA3262218A1 (en) 2022-07-19 2024-01-25 Rampart Bioscience, Inc. CIRCULAR NON-IMMUNOGENEOUS NON-VIRAL DNA VECTORS
WO2024039652A1 (en) * 2022-08-16 2024-02-22 Aldevron, L.L.C. Cell-free method of producing synthetic circular nucleic acid

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5478745A (en) * 1992-12-04 1995-12-26 University Of Pittsburgh Recombinant viral vector system
US6825012B2 (en) * 1995-02-23 2004-11-30 Gencell S.A. DNA molecules, preparation and use in gene therapy
RU2001135838A (ru) * 1999-05-28 2004-01-20 Камбрекс Байо Сайенс Инк. (Us) Способы очистки ДНК и очищенная ДНК
EP1224313A1 (en) * 1999-10-07 2002-07-24 University of Iowa Research Foundation Adeno-associated viruses and uses thereof
AU2001288839A1 (en) * 2000-09-08 2002-03-22 The General Hospital Corporation Self-rearranging dna vectors
US20070196838A1 (en) * 2000-12-08 2007-08-23 Invitrogen Corporation Methods and compositions for synthesis of nucleic acid molecules using multiple recognition sites
AU2002247014A1 (en) * 2001-01-19 2002-07-30 Genetica, Inc. Methods and reagents for amplification and manipulation of vector and target nucleic acid sequences
AU2009231171A1 (en) * 2008-04-02 2009-10-08 Fondazione Telethon Method of treating genetic disorders
US8236548B2 (en) * 2008-07-03 2012-08-07 The Board Of Trustees Of The Leland Stanford Junior University Minicircle DNA vector preparations and methods of making and using the same
US8945885B2 (en) * 2008-07-03 2015-02-03 The Board Of Trustees Of The Leland Stanford Junior University Minicircle DNA vector preparations and methods of making and using the same
EP2439276A1 (de) * 2010-10-05 2012-04-11 Rentschler Biotechnologie GmbH Verfahren zur semi-synthetischen Herstellung hochreiner "MiniCircle" DNA-Vektoren aus Plasmiden
EP2500434A1 (en) * 2011-03-12 2012-09-19 Association Institut de Myologie Capsid-free AAV vectors, compositions, and methods for vector production and gene delivery
US20140350087A9 (en) * 2012-03-22 2014-11-27 Halozyme, Inc. Oncovector Nucleic Acid Molecules and Methods of Use
EP2994531B1 (en) * 2013-05-10 2018-03-28 Sangamo Therapeutics, Inc. Delivery methods and compositions for nuclease-mediated genome engineering
WO2016120186A1 (en) * 2015-01-27 2016-08-04 F. Hoffmann-La Roche Ag Recombinant hbv cccdna, the method to generate thereof and the use thereof
EP3294309A4 (en) * 2015-05-14 2019-01-16 St. Jude Children's Research Hospital, Inc. NUCLEIC ACID MOLECULES WITH SPACERS AND METHOD FOR USE THEREOF
CA3005474A1 (en) * 2015-11-19 2017-05-26 The Trustees Of The University Of Pennsylvania Compositions and methods for correction of heritable ocular disease
MX2018010633A (es) * 2016-03-03 2019-06-13 Univ Massachusetts Acido desoxirribonucleico (adn) lineal duplex de extremos cerrados para transferencia genica no viral.
KR20220128607A (ko) * 2019-09-18 2022-09-21 인터갈락틱 테라퓨틱스, 인크. 합성 dna 벡터 및 사용 방법

Also Published As

Publication number Publication date
CN117757842A (zh) 2024-03-26
AU2019233901A1 (en) 2020-09-17
JP2021516953A (ja) 2021-07-15
CA3092088A1 (en) 2019-09-19
CN111954528A (zh) 2020-11-17
JP2024041819A (ja) 2024-03-27
EP3765023A1 (en) 2021-01-20
EP3765023A4 (en) 2022-01-19
IL276923A (en) 2020-10-29
US20210002667A1 (en) 2021-01-07
WO2019178500A1 (en) 2019-09-19
KR20200132893A (ko) 2020-11-25
US20240247284A1 (en) 2024-07-25

Similar Documents

Publication Publication Date Title
MX2020009579A (es) Vectores de adn sintetico y metodos de uso.
MX2022003291A (es) Vectores de adn sinteticos y metodos de uso.
PH12021550843A1 (en) Nucleic acid constructs and methods of use
WO2019118515A3 (en) Compositions and methods for suppressing pathogenic organisms
MX2025014039A (es) Metodos de terapia genica para enfermedades y condiciones relacionadas con la edad
MX2025014318A (es) Vector de adenovirus de chimpance util para la administracion de neoantigenos
ZA202307880B (en) Human cytomegalovirus comprising exogenous antigens
WO2016109546A3 (en) Methods and compositions for prognosis and treatment of cancers
WO2017077329A3 (en) Nucleic acids, peptides and methods
WO2017218974A3 (en) Treatment of amd using aav2 variant with aflibercept
MY188290A (en) Gold kiwifruit compositions and methods of preparation and use therefor
EP2574170A4 (en) IMMUNOSTIMULATORY AND VACCINE COMPOSITIONS
EP4406585A3 (en) Nucleic acid products and methods of administration thereof
EP4600255A3 (en) Aav vectors for retinal and cns gene therapy
UA120050C2 (uk) Генна терапія для лікування пігментного ретиніту
SG10201808063PA (en) Compositions for modulating ataxin 2 expression
SG11202008687XA (en) Increasing tissue specific gene delivery by capsid modification
EP4707400A3 (en) Gene therapies for lysosomal disorders
MX2019006426A (es) Reguladores de tau, y composiciones y metodos para su administracion.
MY206763A (en) Piperidinyl-3-(aryloxy)propanamides and propanoates
MX2021001460A (es) Metodos y composiciones para secrecion de polipeptidos heterologos.
MX2022006602A (es) Vacunas de herpesvirus de pavo recombinante y uso de las mismas.
MX2021006253A (es) Terapias génicas para enfermedad neurodegenerativa.
WO2016086227A3 (en) Therapeutic compositions comprising transcription factors and methods of making and using the same
WO2018226992A8 (en) Tau aggregation inhibitors